Published online August 1, 2008
PEDIATRICS Vol. 122 No. 2 August 2008, pp. 383-391 (doi:10.1542/peds.2007-2711)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Juul, S. E.
Right arrow Articles by Mayock, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Juul, S. E.
Right arrow Articles by Mayock, D. E.
Related Collections
Right arrow Premature & Newborn
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

ARTICLE

A Phase I/II Trial of High-Dose Erythropoietin in Extremely Low Birth Weight Infants: Pharmacokinetics and Safety

Sandra E. Juul, MD, PhDa, Ronald J. McPherson, PhDa, Larry A. Bauer, PharmDb, Kelly J. Ledbetter, BAa, Christine A. Gleason, MDa and Dennis E. Mayock, MDa

a Departments of Pediatrics
b Pharmacy and Laboratory Medicine, University of Washington, Seattle, Washington

OBJECTIVES. High-dose recombinant erythropoietin is neuroprotective in animal models of neonatal brain injury. Extremely low birth weight infants are at high risk for brain injury and neurodevelopmental problems and might benefit from recombinant erythropoietin. We designed a phase I/II trial to test the safety and determine the pharmacokinetics of high-dose recombinant erythropoietin in extremely low birth weight infants.

METHODS. In a prospective, dose-escalation, open-label trial, we compared 30 infants who were treated with high-dose recombinant erythropoietin with 30 concurrent control subjects. Eligible infants were <24 hours old, ≤1000 g birth weight, and ≤28 weeks of gestation and had an umbilical artery catheter in place. Each infant received 3 intravenous doses of 500, 1000, or 2500 U/kg at 24-hour intervals beginning on day 1 of age. Blood samples were collected at scheduled intervals to determine recombinant erythropoietin pharmacokinetics. Safety parameters were also evaluated. In the concurrent control group, only clinical data were collected.

RESULTS. Mean erythropoietin concentrations 30 minutes after recombinant erythropoietin infusion were 5973 ± 266, 12291 ± 403, and 34197 ± 1641 mU/mL after 500, 1000, or 2500 U/kg, respectively. High-dose recombinant erythropoietin followed nonlinear pharmacokinetics as a result of decreasing clearance from the lowest dosage (17.3 mL/hour per kg for 500 U/kg) to the highest dosage (8.2 mL/hour per kg for 2500 U/kg). Steady state was achieved within 24 to 48 hours. Both 1000 and 2500 U/kg recombinant erythropoietin produced peak serum erythropoietin concentrations that were comparable to neuroprotective concentrations that previously were seen in experimental animals. No excess adverse events occurred in the recombinant erythropoietin–treated infants compared with control infants.

CONCLUSIONS. Early high-dose recombinant erythropoietin is well tolerated by extremely low birth weight infants, causing no excess morbidity or mortality. Recombinant erythropoietin dosages of 1000 and 2500 U/kg achieved neuroprotective serum levels.

Key Words: neonate • preterm • neuroprotection

Abbreviations: ELBW—extremely low birth weight • ICH—intracranial hemorrhage • Epo—erythropoietin • rEpo—recombinant erythropoietin • ROP—retinopathy of prematurity • PVL—periventricular leukomalacia • PDA—patent ductus arteriosus • AUC—area under the curve • NEC—necrotizing enterocolitis • TAOC—total antioxidant capacity • t1/2—half-life • Epo-R—erythropoietin receptor • HSD—honestly significant differences

Accepted Dec 4, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 PediatricsHome page
R. J. McPherson
Can Erythropoietin Improve Developmental Outcomes for Preterm Infants?
Pediatrics, October 1, 2009; 124(4): e805 - e806.
[Full Text] [PDF]

Home page
 PediatricsHome page
M. S. Brown, D. Eichorst, B. LaLa-Black, and R. Gonzalez
Higher Cumulative Doses of Erythropoietin and Developmental Outcomes in Preterm Infants
Pediatrics, October 1, 2009; 124(4): e681 - e687.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
C. Zhu, W. Kang, F. Xu, X. Cheng, Z. Zhang, L. Jia, L. Ji, X. Guo, H. Xiong, G. Simbruner, et al.
Erythropoietin Improved Neurologic Outcomes in Newborns With Hypoxic-Ischemic Encephalopathy
Pediatrics, August 1, 2009; 124(2): e218 - e226.
[Abstract] [Full Text] [PDF]